Reuken, P. A. http://orcid.org/0000-0002-7696-475X
Rüthrich, M. M. http://orcid.org/0000-0001-7577-181X
Hochhaus, A.
Hammersen, J.
Bauer, M. http://orcid.org/0000-0002-1521-3514
La Rosée, P. http://orcid.org/0000-0002-6758-7809
La Rosée, F. http://orcid.org/0000-0002-4310-3582
Stallmach, A. http://orcid.org/0000-0002-6101-5244
Funding for this research was provided by:
Novartis
Celltrion
Article History
Received: 22 July 2021
Revised: 20 August 2021
Accepted: 27 August 2021
First Online: 7 September 2021
Competing interests
: Research support by Novartis to AH, PLR, JH. Outside of the study, AS has received consulting fees from AbbVie, Amgen, Celltrion, Janssen, MSD, Mundipharma, and Takeda; lecture fees and support for travel accommodation from AbbVie, Amgen, FalkFoundation, Janssen, MSD, and Takeda; and research funding from Abbvie and Celltrion. Outside of the study, PAR received consulting and lecture fees from CSL Behring, Dr. Wilmar Schwabe, Boston Scientific, Pfizer, and travel grants from Merz Pharma.